KEY POINTS
- Novo Nordisk’s stock has declined amid rising interest in Eli Lilly’s GLP-1 drugs, although long term investors may see value.
- Eli Lilly’s P/E ratio is 50 compared with Novo Nordisk’s 18, while Novo Nordisk offers a higher dividend yield of 2.8%.
- Novo Nordisk remains the first company to market a GLP-1 pill, potentially attracting oral medication consumers.
COPENHAGEN — Novo Nordisk is navigating a rapidly evolving pharmaceutical landscape as competition intensifies in the GLP-1 weight loss drug market.
The Danish drugmaker, an early pioneer with its diabetes medication Ozempic, which also supports weight management, is facing pressure from Eli Lilly’s newly launched GLP-1 therapies, Mounjaro for diabetes and Zepbound for weight loss.
The global GLP-1 drug market, designed to aid weight loss and diabetes management, has drawn investor attention since Ozempic’s market debut.
Novo Nordisk initially captured headlines for its dual purpose medication, which combined diabetes treatment with significant weight reduction effects.
The entry of Eli Lilly into this space has shifted market dynamics and stock valuations.
GLP-1 receptor agonists have emerged as a fast-growing segment in the pharmaceutical industry due to rising obesity and diabetes rates worldwide.
Novo Nordisk first gained traction in 2014 with Ozempic, leveraging its established diabetes portfolio.
Eli Lilly’s more recent launches, Mounjaro in 2022 and Zepbound in 2025, have prompted investors to reassess market leadership.
“Short term stock fluctuations often reflect investor momentum rather than long term fundamentals,” said Lars Rebien Sørensen, former CEO of Novo Nordisk and senior industry advisor.
“Novo Nordisk’s experience in diabetes, including insulin production, ensures a stable revenue base that new entrants cannot immediately replicate.”
Financial analyst Anne Fischer at Nordea Markets noted, “Eli Lilly’s valuation is high relative to historical norms, which may expose investors to volatility.
Novo Nordisk’s lower P/E and 2.8 percent dividend yield indicate potential undervaluation.”
| Company | P/E Ratio | Dividend Yield | Historical P/E Average |
|---|---|---|---|
| Eli Lilly | 50 | 0.6% | 55 |
| Novo Nordisk | 18 | 2.8% | 30 |
Dr. Maria Jensen, endocrinologist at Rigshospitalet in Copenhagen, said, “The oral GLP-1 pill could appeal to patients hesitant about injections, sustaining Novo Nordisk’s market relevance.”
Investor Henrik Larsen, managing partner at Copenhagen Capital, added, “While Eli Lilly drives headline growth, Novo Nordisk’s diversified diabetes portfolio offers stability that can protect long term shareholders.”
The competitive environment is expected to remain dynamic, with Pfizer and other pharmaceutical companies entering the GLP-1 space.
Novo Nordisk’s leadership in oral medications, combined with its established insulin business, positions the company to maintain steady revenue despite short term market volatility.
Despite Eli Lilly’s rapid gains in GLP-1 weight loss drugs, Novo Nordisk’s pioneering products, valuation metrics, and dividend strength continue to make it a notable player for long term investors seeking exposure to the evolving diabetes and weight management market.
NOTE! This article was generated with the support of AI and compiled by professionals from multiple reliable sources, including official statements, press releases, and verified media coverage. For more information, please see our T&C.
